.jpg "Xenon (NASDAQ: XENE)")
Today, a Director at Xenon, Mohammad Azab, exercised options of Xenon (NASDAQ: XENE) for $38.07K. The options were close to expired and Mohammad Azab retained stocks.
This recent transaction increases Mohammad Azab’s holding in the company by 23.27% to a total of $427.8K. Following Mohammad Azab’s last XENE Buy transaction on November 16, 2017, the stock climbed by 5.6%.
See today’s analyst top recommended stocks >>
Currently, Xenon has an average volume of 94.61K. The Company has a Price to Book ratio of 16.6709.
Starting in December 2014, XENE received 49 Buy ratings in a row. Six different firms, including Canaccord Genuity and Cantor Fitzgerald, currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xenon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in discovering and developing a pipeline of differentiated therapeutics.
